Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism by Bullenkamp, Jessica et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/cddis.2014.455
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Bullenkamp, J., Raulf, N., Ayaz, B., Walczak, H., Kulms, D., Odell, E., ... Tavassoli, M. (2014). Bortezomib
sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent,
E6-independent mechanism. Cell Death and Disease, 5, 1-9. [e1489]. 10.1038/cddis.2014.455
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
OPEN
Bortezomib sensitises TRAIL-resistant HPV-positive
head and neck cancer cells to TRAIL through a
caspase-dependent, E6-independent mechanism
J Bullenkamp1, N Raulf1, B Ayaz2, H Walczak3, D Kulms4, E Odell2, S Thavaraj2 and M Tavassoli*,1
Human papillomavirus (HPV) is causative for a new and increasing form of head and neck squamous cell carcinomas (HNSCCs).
Although localised HPV-positive cancers have a favourable response to radio-chemotherapy (RT/CT), the impact of HPV in
advanced or metastatic HNSCC remains to be defined and targeted therapeutics need to be tested for cancers resistant to RT/CT.
To this end, we investigated the sensitivity of HPV-positive and -negative HNSCC cell lines to TRAIL (tumour necrosis factor-related
apoptosis-inducing ligand), which induces tumour cell-specific apoptosis in various cancer types. A clear correlation was
observed between HPV positivity and resistance to TRAIL compared with HPV-negative head and neck cancer cell lines. All TRAIL-
resistant HPV-positive cell lines tested were sensitised to TRAIL-induced cell death by treatment with bortezomib, a clinically
approved proteasome inhibitor. Bortezomib-mediated sensitisation to TRAIL was associated with enhanced activation of caspase-
8, -9 and -3, elevated membrane expression levels of TRAIL-R2, cytochrome c release and G2/M arrest. Knockdown of caspase-8
significantly blocked cell death induced by the combination therapy, whereas the BH3-only protein Bid was not required for
induction of apoptosis. XIAP depletion increased the sensitivity of both HPV-positive and -negative cells to TRAIL alone or in
combination with bortezomib. In contrast, restoration of p53 following E6 knockdown in HPV-positive cells had no effect on their
sensitivity to either single or combination therapy, suggesting a p53-independent pathway for the observed response. In summary,
bortezomib-mediated proteasome inhibition sensitises previously resistant HPV-positive HNSCC cells to TRAIL-induced cell death
through a mechanism involving both the extrinsic and intrinsic pathways of apoptosis. The cooperative effect of these two targeted
anticancer agents therefore represents a promising treatment strategy for RT/CT-resistant HPV-associated head and neck cancers.
Cell Death and Disease (2014) 5, e1489; doi:10.1038/cddis.2014.455; published online 23 October 2014
Head and neck squamous cell carcinoma (HNSCC) repre-
sents the sixth most common cancer worldwide.1 While the
overall incidence of HNSCC, traditionally associated with
tobacco or alcohol consumption, is declining, a subset of
oropharyngeal cancers caused by infection with high-risk
types of human papillomavirus (HPV) has risen significantly.2,3
Transformation upon HPV infection occurs mainly because of
inactivation of the p53 and retinoblastoma tumour suppressor
proteins mediated by the viral oncoproteins E6 and E7,
respectively.4
HPV-positive (HPV+) cancers represent a distinct subset of
HNSCC in terms of biology and clinical behaviour. In general,
they are characterised by better overall survival and an
improved response to conventional radio-chemotherapy (RT/
CT) compared with HPV-negative (HPV−) cancers.5,6 To
further minimise treatment-related toxicity without compromis-
ing outcome, there have been suggestions of treatment
de-escalation in conjunction with targeted therapies.7
The novel anticancer agent TRAIL (tumour necrosis factor-
related apoptosis-inducing ligand) selectively kills several
types of malignant cell lines with little effect on normal cells.8
Recombinant TRAIL or monoclonal antibodies targeting
TRAIL receptors (TRAIL-Rs) are currently being tested in
phase I/II clinical trials for patients with advanced tumours.9,10
TRAIL induces cell death by binding to TRAIL-R1 or TRAIL-
R2, resulting in receptor oligomerisation and formation of the
death-inducing signalling complex (DISC)11 and activation of
initiator caspase-8.12 Caspase-8 directly activates effector
caspase-3 to induce apoptosis through the type I pathway or
cleaves the BH3-only protein Bid, generating tBid. This type II
pathway involves an amplification loop through the intrinsic
pathway of apoptosis characterised by cytochrome c release
from the mitochondria, activation of initiator caspase-9 and
ultimately caspase-3.13
Despite its tumour-selective activity, various cancer cell
lines remain resistant to TRAIL, limiting the clinical potential of
TRAIL-based monotherapies. Many recent studies focus on
combination strategies with other agents to sensitise resistant
cells to TRAIL.14 The proteasome inhibitor bortezomib is an
FDA-approved drug for the treatment of multiple myeloma, but
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has shown only little single-agent activity in solid malignancies
such as HNSCC while being effective in combination with
other treatment options.15–17 Combining bortezomib with
TRAIL-R agonists produced a synergistic cytotoxic effect in
various types of cancers. Potential mechanisms underlying
sensitisation to TRAIL-induced apoptosis include inhibition of
NF-κB signalling, stabilisation of BH3-only proteins, p53 or
p21, upregulation of TRAIL-Rs and enhanced stability of
caspase-8.18–26
So far, little data is available on the therapeutic potential of
TRAIL alone or in combination with bortezomib in HNSCC or
other HPV+ related cancers. Treatment with the proteasome
inhibitor MG132 sensitised TRAIL-resistant HPV+ cervical
cancer cells to TRAIL through p53-dependent upregulation of
TRAIL-Rs and inactivation of XIAP.27 Overexpression of E6
was shown to protect colon cancer cells from death receptor-
induced apoptosis by affecting the stability of the DISC,
indicating a functional link between the presence of E6 and
TRAIL signalling.28
In this study, we tested the response of HPV+ and HPV−
HNSCC cells to treatment with TRAIL alone or combined with
bortezomib, revealing a clear pattern of sensitivity to TRAIL
depending on HPV status and a synergistic effect when
combined with bortezomib. In addition, we identified some of
the proteins and pathways involved in the response to TRAIL/
bortezomib in HNSCCs.
Results
HPV-associated HNSCC cells are resistant to TRAIL.
HPV+ HNSCCs generally display higher sensitivity to RT/CT
than HPV− cancers,6 but their response to targeted ther-
apeutic agents remains largely unknown. We therefore
investigated the cytotoxic effect of the tumour-selective
apoptosis-inducing agent TRAIL in a panel of HPV+ and
HPV− HNSCC cell lines, demonstrating a link between HPV
status and TRAIL sensitivity. Whereas treatment with
increasing concentrations of recombinant TRAIL reduced
the viability of HPV− cells in a dose-dependent manner, all
HPV+ cell lines tested remained resistant to TRAIL even at
high concentrations (Figure 1a).
Bortezomib sensitises HPV+ HNSCC cells to TRAIL-
induced cell death. The proteasome inhibitor bortezomib
has been shown to sensitise cells to TRAIL in other types of
cancer.29 We therefore aimed to investigate whether con-
centrations of bortezomib with only low single-agent toxicity
synergise with TRAIL in HPV+ HNSCC cells. The represen-
tative site-matched HNSCC cell lines 089 (HPV−) and 090
(HPV+), which demonstrated the highest difference in TRAIL
sensitivity, were selected for further analysis. An initial dose–
response assay revealed a similar response of 089 and 090
cells to treatment with bortezomib with an IC50 value of
~ 2.5 ng/ml (Supplementary Figure 1). The combined effect of
Figure 1 Sensitisation of HPV+ HNSCC cells to TRAIL by proteasome inhibition. (a) Seven HPV− or HPV+ HNSCC cell lines were treated with increasing concentrations of
TRAIL up to 100 ng/ml for 72 h. Cell viability after treatment was analysed by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay of triplicate wells. Bars
represent mean cell viability normalised to untreated control cells and error bars indicate S.E.M. of three independent experiments. (b) The 089 and 090 cells were treated with the
indicated concentrations of TRAIL and/or bortezomib (Btz) for 48 h and analysed by MTTassay as before in four independent experiments. P-values were determined by two-way
analysis of variance (ANOVA) (*Po0.05 and ***Po0.001). (c) The 089 and 090 cells were treated with 50 ng/ml TRAIL and 2.5 ng/ml Btz alone or in combination. Cells were
collected at the indicated time points for Annexin V/PI staining and fluorescence-activated cell sorting (FACS) analysis. Bars indicate the mean percentage of dead cells defined as
either Annexin V or PI positive and error bars indicate S.E.M. of three independent experiments. P-values were determined by two-way ANOVA (**Po0.01 and ***Po0.001).
(d) Seven HNSCC cell lines were treated with single drugs or the combination of 50 ng/ml TRAIL and 2.5 ng/ml bortezomib for 48 h and analysed by MTTassay as before in three
independent experiments. P-values were determined by two-way ANOVA (*Po0.05, **Po0.01, NSP40.05). (e) The 090 cells were treated with 50 ng/ml TRAIL and 0.1 μM
MG132 for 48 h until MTT analysis as before in three independent experiments. P-values were determined by two-way ANOVA (**Po0.01)
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both drugs was tested using 50 ng/ml TRAIL in combination
with bortezomib at several concentrations below the IC50
value. Cotreatment with bortezomib sensitised HPV+ 090
cells to TRAIL-induced cell death, whereas bortezomib alone
did not markedly impair cell viability (Figure 1b). This effect
was highly synergistic with a combination index below 0.5
(data not shown). In addition, TRAIL-induced cell death in
HPV− 089 cells was further enhanced by bortezomib
(Figure 1b).
The decrease in cell viability measured by MTT assays
might also be because of bortezomib-induced cell cycle arrest
reducing the number of viable cells. To determine whether
combination treatment with TRAIL and bortezomib (TRAIL/
bortezomib) triggers apoptosis in HNSCC cell lines, 089 and
090 cells were analysed by flow cytometry at the indicated
time points (Figure 1c). Cell death, defined as positive staining
for Annexin Vor PI, was detected in both cell lines treated with
TRAIL and bortezomib in combination. In contrast, TRAIL
alone did not affect the viability of 090 cells but induced cell
death in 089 cells, whereas bortezomib as a single drug
displayed only slight toxicity in both cell lines.
A similar effect of bortezomib on TRAIL-induced cell death
was also observed in a larger panel of HPV+ and HPV−
HNSCC cell lines. Cotreatment with TRAIL and bortezomib
significantly reduced cell viability in all HPV+ cell lines
compared with single treatments (Figure 1d). Overall, these
results suggest that TRAIL-resistant HPV+ HNSCC cells
become highly sensitive to TRAIL to a similar level as HPV−
cells when additionally treated with bortezomib.
To examine whether the sensitising effect of bortezomib is
due to proteasome inhibition, another proteasome inhibitor,
MG132, was tested in combination with TRAIL. Similar to
bortezomib, cotreatment with a subtoxic dose of MG132
sensitised HPV+ 090 cells to TRAIL-induced cell death
(Figure 1e).
TRAIL and bortezomib combination treatment induces
caspase-dependent cell death. In addition to apoptosis
TRAIL has also been implicated in necroptotic cell death.30
To analyse the type of cell death, 089 and 090 cells were pre-
treated with the pancaspase inhibitor z-Vad-fmk (zVad) and/
or the RIP1 kinase inhibitor necrostatin-1 (nec-1) followed by
treatment with TRAIL/bortezomib. Pre-treatment with zVad
significantly rescued both cell lines from TRAIL/bortezomib-
induced cell death, increasing cell viability by ~ 30%. Further
combination treatment with nec-1 provided significant addi-
tional protection by about 20%, which might indicate a
necroptotic cell death induced by TRAIL/bortezomib in
HNSCC cells (Figure 2a). These results were confirmed by
Annexin V/PI staining after treatment of 089 and 090 cells
with TRAIL/bortezomib plus zVad and/or nec-1. Addition of
zVad alone or combined with nec-1 had a protective effect in
both cell lines, reducing cell death by up to 40% (Figure 2b),
confirming that TRAIL/bortezomib induce caspase-
dependent cell death.
The activation of specific caspases in HPV+ 090 cells in
response to the combination treatment was further analysed.
Marked processing of caspase-3, generating the active
17 kDa fragment, and a slight reduction of procaspase-8
levels were only detected following treatment with TRAIL/
bortezomib but not TRAIL alone (Figure 2c). Combination
treatment but not individual drugs induced activation of
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Figure 2 TRAIL and bortezomib cooperate to induce caspase-dependent apoptosis. (a) The 089 and 090 cells were treated with 50 ng/ml TRAIL and 2.5 ng/ml BTZ alone or
in combination with the caspase inhibitor zVad (20 μM) and/or the RIP1 kinase inhibitor nec-1 (50 μM). Cell survival was measured 24 h later by 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) analysis. Bars represent mean cell viability normalised to untreated control cells and error bars indicate S.E.M. of four independent
experiments. P-values were determined by two-way ANOVA (*Po0.05, **Po0.01 and ***Po0.001). (b) Quantification of Annexin Vand PI single- or double-positive populations
in 089 and 090 cells treated with 50 ng/ml TRAIL and 2.5 ng/ml bortezomib combined with zVad and/or nec-1 as before. Bars represent the percentage of dead cells that were
stained positive for Annexin V, PI or both and error bars indicate S.E.M. of three independent experiments. P-values were determined by one-way ANOVA (**Po0.01 and
***Po0.001). (c) Western blot analysis of caspase-3, -8 and -9 processing in 090 cells treated with TRAIL (T, 50 ng/ml) and bortezomib (B, 2.5 ng/ml) alone or in combination
(BT) for 16 h. (d) Cytochrome c release was analysed by western blot analysis of cytosolic fractions from 090 cells treated with TRAIL (T, 50 ng/ml) and bortezomib (B, 2.5 ng/ml)
alone or in combination (BT) for 20 h
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caspase-9 as shown by the reduction in full-length caspase-9
levels and generation of the active 37 kDa fragment. This
suggests activation of the intrinsic pathway of apoptosis, which
is characterised by the release of cytochrome c from the
mitochondria into the cytosol.31 Cytochrome cwas detected in
cytosolic fractions of 090 cells following combination treatment
with TRAIL and bortezomib, hinting towards an involvement of
the intrinsic pathway (Figure 2d).
Bortezomib-mediated sensitisation to TRAIL is associated
with upregulation of TRAIL-R2 and requires caspase-8
but not Bid. Proteasome inhibition has previously been
associated with increased transcription and membrane
expression of TRAIL-R2.18,32 We therefore analysed the
surface expression levels of TRAIL-Rs in 089 and 090 cells
by flow cytometry. Measurement of basal receptor levels
showed expression of TRAIL-R2 in both cell lines, whereas
TRAIL-R1 was only detectable in 089 cells (Figure 3a and
Supplementary Figure 2). Bortezomib treatment triggered a
modest but significant increase in expression levels of TRAIL-
R2 but not TRAIL-R1 in 090 cells. This might contribute to the
increased TRAIL sensitivity of 090 cells; however, further
studies will be required to determine whether TRAIL-R
upregulation is necessary for TRAIL sensitisation by
bortezomib.
Themajor initiator caspase recruited to the activated TRAIL-
R complex is caspase-8. Knockdown of caspase-8 in 089 and
090 cells (knockdown efficiency 80–100%) markedly reduced
processing of caspase-3 in response to the combination
treatment (Figure 3b). Moreover, it significantly increased cell
survival in both cell lines following treatment with TRAIL/
bortezomib by ~40% compared with control cells (Figures 3c
and d and Supplementary Figure 3). The remaining cytotoxic
effect could be due to residual levels of caspase-8 or activation
of other initiator caspases compensating for caspase-8
deficiency.
The truncated form of Bid, tBid, links death receptor
activation to the intrinsic pathway and is stabilised by
proteasome inhibition, representing a potential mechanism
for sensitisation to TRAIL by bortezomib.25 The effect of Bid
depletion on the sensitivity to TRAIL/bortezomib was studied
using stable 089 and 090 Bid shRNA cells (knockdown
efficiency 70%; Figure 3e). No significant difference in the
response to TRAIL and/or bortezomib was observed between
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Figure 3 Bortezomib-induced sensitisation involves upregulation of DR5 and is mediated by caspase-8 but not Bid. (a) The 089 and 090 cells were treated with 2.5 ng/ml
bortezomib (Btz) for 20 h. The surface expression of TRAIL-Rs was assessed by flow cytometry following staining with monoclonal antibodies for TRAIL-R1 (DR4) or TRAIL-R2
(DR5) and a secondary anti-mouse fluorescein isothiocyanate (FITC)-coupled antibody. Bars represent mean fluorescence intensity of FITC corrected for staining with a
nonspecific isotype control and error bars indicate S.E.M. of three independent experiments. P-values were determined by one-way analysis of variance (ANOVA) (**Po0.01).
(b) Stable inducible 089 and 090 caspase-8 (C8) and scrambled control (scr) short hairpin RNA (shRNA) cells were generated by lentiviral infection and shRNAs were induced
with 1 μg/ml doxycycline for 24 h. Caspase-3 and -8 levels following treatment with 50 ng/ml TRAIL and 2.5 ng/ml bortezomib (BT) for 16 h were assessed by western blot
analysis compared with respective control cells. The efficiency of caspase-8 knockdown was calculated using ImageJ software normalised to β-actin. Blots were cut and
combined at the indicated line. (c and d) Cell viability of 089 (c) and 090 (d) C8 and scr shRNA cells after induction with 1 μg/ml doxycycline in the presence of 50 ng/ml TRAIL
and/or 1 ng/ml Btz was analysed by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay after 48 h of treatment. Bars represent mean cell viability
normalised to untreated control cells and error bars indicate S.E.M. of three independent experiments. P-values were determined by two-way ANOVA comparing C8 shRNA with
corresponding control cells (**Po0.01 and ***Po0.001). (e) Stable Bid and non-silencing control shRNA 089 and 090 cells were generated by lentiviral infection. The efficiency
of Bid knockdown in both cell lines was assessed by western blot analysis compared with respective control cells and calculated using ImageJ software normalised to β-actin.
(f and g) Cell viability of 089 (f) and 090 (g) Bid and control shRNA cells in the presence of 50 ng/ml TRAIL and/or 1 ng/ml Btz as indicated was analysed by MTTanalysis after
48 h. Bars represent mean cell viability normalised to untreated control cells and error bars indicate S.E.M. of three independent experiments
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Bid knockdown and control cells (Figures 3f and g), indicating
that bortezomib-induced sensitisation to TRAIL occurs inde-
pendently of Bid.
XIAP depletion increases cell death in response to TRAIL
alone and in combination with bortezomib. The anti-
apoptotic protein XIAP prevents caspase-3 activation and its
inhibition has been linked to increased sensitivity to
TRAIL.33,34 Stable knockdown of XIAP in 090 cells (knock-
down efficiency 70%) resulted in enhanced caspase-3
activation in response to bortezomib alone or in combination
with TRAIL, as evident by increased caspase-3 processing
and cleavage of PARP, but did not markedly affect caspase-3
activation following treatment with TRAIL alone at this time
point (Figure 4b). In contrast, stable 089 XIAP knockdown
cells (knockdown efficiency 80%) showed increased proces-
sing and activity of caspase-3 in response to the combination
treatment as well as TRAIL alone.
XIAP knockdown reduced the survival of 089 cells in
response to TRAIL to a similar level as obtained in combina-
tion with bortezomib, but did not affect their sensitivity to
bortezomib alone (Figure 4c). Importantly, TRAIL-resistant
090 cells were significantly sensitised to TRAIL following XIAP
knockdown, which reduced cell viability in response to TRAIL
alone by ~ 30% (Figure 4d). In both cell lines, depletion of XIAP
significantly enhanced cell death after combination treatment
with TRAIL and bortezomib at all concentrations tested.
Bortezomib-induced p53 stabilisation in HPV+ cells is not
the main mechanism for TRAIL sensitisation. In HPV+
tumours, p53 is kept inactive through E6-mediated proteaso-
mal degradation,35 whereas HPV− HNSCCs often contain
inactivating p53 mutations, resulting in a stabilised but non-
functional protein. Bortezomib treatment of HPV+ HNSCC
cell lines has previously been associated with p53 stabilisa-
tion and induction of p53-dependent cell cycle arrest and
apoptosis.36 Here we show that bortezomib induces restora-
tion of p53 and induction of the p53 target protein p21 in all
HPV+ cell lines tested with the exception of 147 T cells that
already showed a marked basal p53 expression (Figure 5a).
By contrast, HPV− 089 and 072 cells, which contain mutated
p53,37 showed no further increase in p53 protein levels and
only a minimal induction of p21 in 072 cells.
To test the importance of p53 for the response of HPV+ cells
to TRAIL/bortezomib, stable E6 shRNA 090 cells were
generated. Western blot analysis showed almost ninefold
increased levels of p53 in E6 knockdown cells compared with
control cells, indicating reduced degradation of p53 after E6
depletion. E6 shRNA and control cells were subsequently
treated with TRAIL alone or in combination with bortezomib for
analysis of cell viability, but showed no significant difference in
the response to either drug (Figures 5c and d). These results
suggest that TRAIL resistance in 090 cells is not because of
the presence and activity of E6 and that p53 restoration is
insufficient to sensitise cells to TRAIL.
P21 represents a major mediator of p53-induced cell cycle
arrest in the G0/G1 phase in response to DNA-damaging
agents and other cellular stresses.38 Flow cytometry-based
cell cycle analysis of bortezomib-treated HNSCC cells
showed a strong G2/M arrest of up to 50% in all cell lines
and a small increase in the sub-G1 population, indicating
apoptotic cells (Figure 5e). The extent of G2/M arrest was
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more pronounced in HPV− cells compared with HPV+ cells
(Figure 5f), which might reflect their generally faster cellular
proliferation rate (data not shown). However, the importance of
this bortezomib-induced G2/M arrest for TRAIL-induced cell
death in HNSCC cells requires further investigation.
Discussion
HPV+ HNSCCs are characterised by improved overall and
disease-specific survival compared with site- and age-
matched controls.5 However, HPV status does not currently
influence management of the disease and existing treatment
modalities are associated with severe side effects. It is
therefore necessary to investigate the impact of dose
de-escalation and novel targeted therapeutic agents in this
group of patients with the aim of maintaining efficacy while
minimising toxicity. One such novel tumour-selective agent is
TRAIL, and despite early promising result in other cancers,8
little is known about its effectiveness in HNSCC.
In contrast to the site-matched HPV− cell lines tested here,
HPV+ HNSCC cells were found to be highly resistant to TRAIL
when used as a single agent even at high concentrations.
There was no clear association between TRAIL resistance in
HPV+ cells and endogenous levels of anti- or proapoptotic
proteins such as TRAIL-Rs, caspase-3/-8 or XIAP (data not
shown). However, expression profiling of a larger panel of
regulatory proteins of apoptosis in a cohort of HPV+ and HPV−
HNSCC samples remains necessary to identify differentially
expressed proteins that contribute to the distinct response
pattern described here. From a clinical perspective, our data
suggest that TRAIL is unlikely to be efficacious as a single
modality treatment option for the management of HPV+ head
and neck cancers.
The function of many proteins involved in death receptor
signalling and apoptosis induction is regulated by
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(e) Seven HNSCC cell lines were treated with 2.5 ng/ml Btz for 24 h before cell cycle analysis by flow cytometry. Representative histograms indicating cells in the respective cell
cycle phases are shown. (f) Bars represent increase of the percentage of cells in the G2/M phase following treatment with 2.5 ng/ml bortezomib for 24 h compared with untreated
control cells and error bars indicate S.E.M. of three independent experiments
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ubiquitination and subsequent proteasomal degradation.39 In
various other TRAIL-resistant cancer cells, including cell lines
derived from squamous cell carcinomas, inhibition of protea-
somal activity resulted in enhanced sensitivity to TRAIL-
induced cell death.22,23 Here we show that combination
treatment with recombinant TRAIL and low doses of the
clinically approved proteasome inhibitor bortezomib displays
synergistic cytotoxicity in all HPV+ HNSCC cell lines tested.
While bortezomib treatment alone showed only a slight effect
on the activation of apoptotic pathways, bortezomib markedly
enhanced TRAIL-induced apoptosis in HNSCC cells, accom-
panied by increased processing of caspase-3, -8 and -9. A
recent study demonstrated increased activity of recombinant
TRAIL in patient-derived ovarian carcinoma cells when
combined with bortezomib, while primary hepatocytes
remained resistant, indicating low toxicity of the combination
treatment in normal cells.40 The combined cytotoxic effect of
bortezomib and TRAIL in both HPV+ and HPV− cell lines
suggests a promising novel therapeutic approach for the
effective and selective killing of HNSCCs.
A number of preclinical studies in other types of cancer have
identified mechanisms underlying the sensitisation of cancer
cells to TRAIL by bortezomib. These include increased
expression of TRAIL-Rs,21,32 enhanced activation of caspase-
8,26 stabilisation of BH3-only proteins,19,25 inactivation of
XIAP27,34 or induction of p53 or p21.20,27 Based on these
studies, we aimed to investigate pathways that contributed to
the increased sensitivity of HNSCC cells to TRAIL when
combined with bortezomib.
Consistent with other studies, bortezomib treatment of
HPV+ cells was associated with elevated membrane expres-
sion levels of TRAIL-R2.18,32 While this modest increase is
unlikely to be the sole mechanism for the observed synergy, it
may contribute to TRAIL sensitivity because of an increased
number of receptors on the cell surface and therefore a higher
degree of caspase-8 activation. Procaspase-8 levels were
slightly reduced in HPV+ cells following combination treatment
with TRAIL and bortezomib, suggesting enhanced activation
of caspase-8 compared with single treatments. Moreover,
bortezomib might also stabilise the active caspase-8 fragment
to enhance its activity as suggested by recent reports that
provided evidence for its regulation through ubiquitination and
degradation.41 Depletion of caspase-8 resulted in markedly
reduced processing of caspase-3 and provided significant
protection against TRAIL/bortezomib in both HPV+ and HPV−
cells. Nevertheless, ~ 50% of cells remained sensitive to
combination treatment with TRAIL/bortezomib in the absence
of caspase-8, which might indicate a role for another initiator
caspase such as caspase-10.
TRAIL and bortezomib in combination triggered cytochrome
c release and activation of caspase-9, indicating induction of
the mitochondrial pathway of apoptosis. The stability of the
truncated form of the BH3-only protein Bid, which triggers the
permeabilisation of the mitochondrial membrane after clea-
vage by active caspase-8, is regulated by proteasomal
degradation.42 In glioblastoma cells, bortezomib-mediated
stabilisation of tBid was shown to facilitate TRAIL-induced cell
death by amplifying apoptosis through the mitochondrial
pathway.24,25 In HNSCC cells, depletion of Bid had no effect
on the cytotoxicity of TRAIL and bortezomib, suggesting that
bortezomib-mediated sensitisation of HPV+ cells to TRAIL is
independent of Bid and that TRAIL-induced apoptosis is
mediated through the type I pathway. Activation of the intrinsic
apoptotic pathway in response to the combination treatment,
as evident by cytochrome c release and cleavage of caspase-
9, potentially represents a parallel cellular process triggered
by bortezomib but is unlikely to be the decisive mechanism of
cell death.18
XIAP prevents the activation of caspase-3 and -9 at different
levels, including inhibition of substrate binding and proteaso-
mal degradation of processed caspase-3 forms.43 Down-
regulation or inhibition of XIAP has been proposed as a
mechanism of bortezomib-induced sensitisation to TRAIL in
different cancer models.34,44,45 In our system, depletion of
XIAP partially sensitised HPV+ cells to TRAIL and significantly
enhanced the synergistic effect of bortezomib. Similar data
were obtained in HPV+ cervical cancer cells in which XIAP
downregulation increased TRAIL-induced apoptosis, in parti-
cular when combined with MG132.27 Moreover, the sensitising
effect of proteasome inhibition to TRAIL in lymphoma cells
with acquired TRAIL resistance could be partially reproduced
by knockdown of XIAP.46 These findings suggest that XIAP
partially accounts for the resistance of HPV+ cells to TRAIL as
a single treatment. In addition to cytochrome c, several other
factors are released into the cytosol upon activation of the
mitochondrial pathway of apoptosis, including Smac/DIABLO
that neutralises the activity of XIAP.47 Bortezomib-induced
permeabilisation of the outer mitochondrial membrane might
therefore result in reduced activity of XIAP to facilitate the full
processing of caspase-3 in response to TRAIL stimulation and
induction of apoptosis in HPV+ cells.
In contrast to many other HNSCCs, HPV-associated
tumours retain wild-type p53 that is inactivated by proteasomal
degradation through E6 and AP.35 Restoration of p53
expression following proteasome inhibition or E6 downregula-
tion was shown to trigger cell cycle arrest and apoptosis in
HPV+ HNSCC cells.4,36 In addition, sensitisation of HPV+
cervical cancer cells to TRAIL by proteasome inhibition
involved upregulation of p53.27,48 Induction of p53 after
treatment with chemotherapeutic agents can increase TRAIL
sensitivity because of the upregulation of death receptors DR4
and DR5.49 Although we observed bortezomib-induced
stabilisation of p53 in all HPV+ cell lines tested, increased
levels of p53 following depletion of E6 were insufficient to
sensitise cells to TRAIL. Similar results were obtained
previously in HPV-associated cervical cancer cells where
transient downregulation of E6 did not confer sensitivity to
death receptor-mediated apoptosis.48 Our data therefore do
not support a role for the E6 oncoprotein in causing TRAIL
resistance. Additionally, stabilisation of p53 by bortezomib is
unlikely to be responsible for sensitisation to TRAIL.
A recent study suggests that TRAIL can exert enhanced
cytotoxic activity in cells arrested in G1 or G2 phase.50 Here,
bortezomib alone induced clear G2/M arrest in all HPV+ and
HPV− HNSCC cell lines, which might contribute to their
increased sensitivity to TRAIL. While these data point to a
potential role for bortezomib-mediated cell cycle arrest, the
precise mechanism of sensitisation to TRAIL remains to be
determined in future studies.
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In conclusion, this study shows that the combination of TRAIL
and bortezomib efficiently induces apoptosis through both the
death receptor and mitochondrial pathway in TRAIL-resistant
HPV+ HNSCC cells and enhances TRAIL-mediated cell death
in HPV− cells. This combination treatment might therefore
represent a novel therapeutic option for drug-resistant HPV+
head and neck cancers. However, further investigations,
including a larger panel of cell lines and in vivo studies, are
required to warrant future clinical application of these com-
pounds for the treatment of head and neck cancer patients.
Materials and Methods
Cell lines and reagents. Five HPV+ and two HPV− cell lines were obtained
from various sources and tested for their respective HPV status (Supplementary
Table 1). The HPV− cell lines UPCI:SCC089 (089) and UPCI:SCC072 (072), as well
as the HPV+ cell lines UPCI:SCC090 (090), UPCI:SCC152 (152) and UPCI:SCC154
(154), were a gift from Professor Susanne Gollin, University of Pittsburgh
(Pittsburgh, PA, USA). The HPV+ cell lines UD-SCC2 (UD2) and VU147-T (147 T)
were provided by Professor Henning Bier, University of Munich (München,
Germany) and Professor Renske Steenbergen, VU University Amsterdam
(Amsterdam, The Netherlands), respectively. All UPCI cell lines and UD-SCC2
cells were cultured in MEM with Earle's salts supplemented with 10% FBS, 2 mM
L-glutamine, 100 μg/ml gentamicin and 1 ×MEM non-essential amino acids. VU147-
T cells were cultured in DMEM high glucose supplemented with 10% FBS, 50 μg/ml
streptomycin, 100 μg/ml penicillin and 1 mM sodium pyruvate (all cell culture
reagents were obtained from PAA Laboratories, Pasching, Austria).
Recombinant human isoleucine zipper trimerised TRAIL was provided by
Professor Henning Walczak, University College London (London, UK). The
pancaspase inhibitor zVad was purchased from Promega (Southampton, UK), the
proteasome inhibitor MG132 from Sigma-Aldrich (Poole, UK) and nec-1 from
StressMarq (Victoria, BC, Canada). Bortezomib was obtained through the Guy’s
Hospital Pharmacy (London, UK).
MTT cell viability assay. Cells were seeded in 96-well plates at a density of
104 cells per well and treated with TRAIL and/or bortezomib after 24 h. For inhibitor
studies, cells were pre-treated for 1 h with 20 μM zVad and 50 μM nec-1 was
included in the treatment. At the indicated times, 20 μl MTT reagent (5 mg/ml;
Calbiochem, Watford, UK) was added, followed by incubation for 2–3 h and addition
of 150 μl MTT solubilisation solution (50% dimethylformamide, 0.2% glacial acetic
acid, 20 mM HCl, 10% SDS). After incubation overnight, the OD595 was measured
on a LT-4000 microplate reader (Labtech, Uckfield, UK).
Statistical analysis of the results from at least three independent experiments as
indicated was performed using GraphPad Prism 6 software (Graphpad Software Inc.,
La Jolla, CA, USA) and one- or two-way ANOVA as appropriate and specified. Drug
synergy was determined using CompuSyn software (ComboSyn Inc., Paramus, NJ,
USA) according to the Chou-Talalay method.51
Western blot analysis. Cells were trypsinised, washed in PBS and
resuspended in lysis buffer (2 mM MgCl2, 25 mM HEPES, 2 mM EGTA, 0.1% Triton
X-100) including protease inhibitors. After 30 min incubation on ice, protein lysates
were obtained by centrifugation for 15 min at 16 000 × g. Forty to sixty micrograms of
protein was used for further immunoblot analysis as described previously.52
Cytosolic fractions were isolated as described previously.53 Briefly, cells of four
confluent 15 cm plates were harvested for each condition, cells were washed two times
with PBS and resuspended 1 : 1 in ice-cold IBc buffer (10 mM Tris, pH 7.5, 1 mM
EGTA, 200 mM sucrose, plus protease inhibitor cocktail). After 30 min incubation, cells
were lysed using a 26 G syringe until ~ 60% of cells were Trypan blue positive. Several
centrifugation steps were performed at 700 to 1200 × g for 5 min at 4 °C to remove
intact cells. The supernatant was centrifuged at 16 000 × g for 30 min at 4 °C to obtain
the cytosolic/ER fraction of which 100 μg was used for immunoblot analysis.
Antibodies used for immunoblotting were: β-actin, tubulin (Sigma-Aldrich),
caspase-3, caspase-9, PARP, Bid, p21 (Cell Signalling, Danvers, MA, USA),
caspase-8 (Enzo Life Sciences, Exeter, UK), XIAP (BD Transduction Laboratories,
Oxford, UK), cytochrome c (Abcam, Cambridge, UK) and p53 (Novocastra, Leica
Biosystems, Milton Keynes, UK). Secondary HRP-coupled anti-rabbit and anti-mouse
antibodies were obtained from GE Healthcare (Chalfont St. Giles, UK) and
Sigma-Aldrich, respectively. The relative expression levels of proteins were
normalised to β-actin using ImageJ software (NIH, Bethesda, MD, USA).
Flow cytometry. Cells were cultured on 24-well plates at a density of 5 × 104
cells per well and treated with the indicated drugs the next day. Cells were collected at
the specific time points by trypsinisation. Apoptosis was quantified by staining with
Annexin V-FITC (BD Pharmingen, Oxford, UK) and propidium iodide (PI; Sigma-
Aldrich). For cell cycle analysis, cells were fixed in 70% ethanol at − 20 °C and stained
with DNA staining solution containing PI and RNase A (Sigma-Aldrich) for 30 min. All
data were acquired on a BD FACSCanto II cytometer (Beckton-Dickinson, Oxford, UK)
and analysed using FlowJo software (Tree Star Inc., Ashland, OR, USA).
For measurement of death receptor expression cells were cultured on 6-well plates
at a density of 3 × 105 cells per well and treated with bortezomib the next day. Cells
were collected by scraping in PBS and centrifuged for 5 min at 1000 × g and 4 °C. Cell
pellets were incubated with primary antibodies HS101 (TRAIL-R1, provided by
Professor Henning Walczak, University College London, London, UK) and HS201
(TRAIL-R2) or an isotype control (mouse IgG; Sigma-Aldrich) at a concentration of
10 μg/ml for 30 min on ice. Following washing with ice-cold FACS buffer (4% FBS in
PBS), a secondary anti-mouse FITC-coupled antibody (Sigma-Aldrich) was added
and cells were incubated for 20 min on ice. Samples were centrifuged for 2 min at
800 × g and the pellet was resuspended in FACS buffer before acquisition of data on a
BD FACSCanto II flow cytometer.
Lentiviral shRNA knockdown. Lentiviral vectors were produced in
HEK293T cells transfected with the second-generation packaging plasmid pCMVΔ8.91
and plasmid pMDG encoding VSV-G-pseudotyped envelope, as well as the construct
of interest by calcium phosphate precipitation. At 24, 36 and 48 h after transfection,
viral supernatants were harvested, filtered through a 0.45 μm filter and stored at − 70 °C
supplemented with 5 μg/ml polybrene. After transduction of target cells with the
lentivirus, infected cells were selected in the presence of appropriate antibiotics.
A mixture of five Bid shRNA constructs including a non-silencing control shRNAwere
kindly provided by Professor Simone Fulda, University Hospital Frankfurt (Frankfurt am
Main, Germany) (Supplementary Table 2). The XIAP shRNA as well as LacZ shRNA
constructs were obtained from Professor Hamid Kashkar, University of Cologne (Köln,
Germany).54 Inducible caspase-8 and respective scrambled shRNA vectors were
provided by Professor Pascal Meier, Institute of Cancer Research (London, UK)
(Supplementary Table 2). The constructs for E6 and corresponding scrambled control
shRNA were purchased from Santa Cruz (Heidelberg, Germany; sc-156008).
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